All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 67 points (-0.4%) at 18,405 as of Thursday, July 28, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,296 issues advancing vs. 1,538 declining with 200 unchanged.

The Health Services industry currently sits up 0.4% versus the S&P 500, which is down 0.2%. On the negative front, top decliners within the industry include

HCA Holdings

(

HCA

), down 1.5%,

Edwards Lifesciences

(

EW

), down 1.5%,

Cigna

(

CI

), down 1.0%,

Baxter International

(

BAX

), down 0.7% and

Alibaba Group

(

BABA

), down 0.6%. Top gainers within the industry include

Alere

(

ALR

), up 23.2%,

Centene

(

CNC

), up 3.1%,

Fresenius Medical Care AG & Co. KGaA

(

FMS

), up 1.4%,

Boston Scientific

(

BSX

), up 1.3% and

Abbott Laboratories

(

ABT

), up 1.1%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Grifols

(

GRFS

) is one of the companies pushing the Health Services industry lower today. As of noon trading, Grifols is down $0.65 (-3.8%) to $16.60 on heavy volume. Thus far, 1.2 million shares of Grifols exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $16.51-$17.02 after having opened the day at $16.86 as compared to the previous trading day's close of $17.25.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Grifols, S.A., a biopharmaceutical company, develops, manufactures, and distributes plasma derivative products in the United States, Canada, Spain, rest of the European Union, and internationally. Grifols has a market cap of $11.7 billion and is part of the health care sector. Shares are up 6.5% year-to-date as of the close of trading on Wednesday. Currently there is 1 analyst that rates Grifols a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Grifols

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels, good cash flow from operations and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Grifols Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Mednax

(

MD

) is down $5.68 (-7.5%) to $69.67 on heavy volume. Thus far, 2.1 million shares of Mednax exchanged hands as compared to its average daily volume of 525,500 shares. The stock has ranged in price between $67.93-$72.62 after having opened the day at $71.28 as compared to the previous trading day's close of $75.35.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

MEDNAX, Inc., together with its subsidiaries, provides neonatal, anesthesia, maternal-fetal, and other pediatric subspecialties physician services in the United States and Puerto Rico. Mednax has a market cap of $7.0 billion and is part of the health care sector. Shares are up 5.2% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Mednax a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Mednax

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and growth in earnings per share. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Mednax Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Humana

(

HUM

) is down $1.15 (-0.7%) to $170.92 on light volume. Thus far, 240,948 shares of Humana exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $170.87-$172.35 after having opened the day at $171.36 as compared to the previous trading day's close of $172.07.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Humana Inc., together with its subsidiaries, operates as a health and well-being company. The company operates through three segments: Retail, Group, and Healthcare Services. Humana has a market cap of $25.9 billion and is part of the health care sector. Shares are down 3.6% year-to-date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Humana a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Humana

as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Humana Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health services industry could consider

ProShares Ultra Short Health Care

(

RXD

).